Jen-Liang Su

3.9k citations
35 papers · 2.5k indexed · h-index 27
Topics
Lymphatic System and Diseases (7 papers)Angiogenesis and VEGF in Cancer (7 papers)TGF-β signaling in diseases (5 papers)
Partner nations
TaiwanUnited StatesChina

In The Last Decade

Jen-Liang Su

35 papers receiving 2.5k citations

Peers

Jen-Liang Su
Comparison fields: 5 of 107
  • Molecular Biology 1.8k
  • Oncology 863
  • Cancer Research 780
  • Immunology 275
  • Genetics 165
Replace Toshiyuki Sakamaki with:
Toshiyuki Sakamaki United States
Pascal Colosetti France
Meidan Ying China
Xiaoping Zhao China
Shine‐Gwo Shiah Taiwan
Jer-Yen Yang United States
Lili Jiang China
Yadi Wu United States
Ming‐Tat Ling Hong Kong
Jen-Liang Su relative to Toshiyuki Sakamaki United States Toshiyuki Sakamaki's profile →
Citations per field
00.5×1.6×
Toshiyuki Sakamaki · 1×
Citations per year

Countries citing papers authored by Jen-Liang Su

Since Specialization
Citations

This map shows the geographic impact of Jen-Liang Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jen-Liang Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jen-Liang Su more than expected).

Fields of papers citing papers by Jen-Liang Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jen-Liang Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jen-Liang Su. The network helps show where Jen-Liang Su may publish in the future.

Co-authorship network of co-authors of Jen-Liang Su

This figure shows the co-authorship network connecting the top 25 collaborators of Jen-Liang Su. A scholar is included among the top collaborators of Jen-Liang Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jen-Liang Su. Jen-Liang Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 128
2 29
3 29
4 26
5 25
6 25
7 39
8 45
9 57
10 125
11 39
12 125
13 51
14 50
15 70
16 277
17 165
18 173
19 31
20 153

About Jen-Liang Su

Jen-Liang Su is a scholar working on Cancer Research, Oncology and Immunology and Allergy, having authored 35 papers that have together received 2.5k indexed citations. Recurring topics across this work include Lymphatic System and Diseases (7 papers), Angiogenesis and VEGF in Cancer (7 papers) and TGF-β signaling in diseases (5 papers). The work is most often cited by research in Cancer Research (780 citations), Oncology (863 citations) and Molecular Biology (1.8k citations). Jen-Liang Su has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Min‐Liang Kuo, Lin‐Hung Wei, Mien‐Chie Hung, Pan‐Chyr Yang, Jin‐Yuan Shih, Yung‐Ming Jeng, Pai‐Sheng Chen, Cheng‐Chi Chang, Ching‐Yao Yang and Michael Hsiao. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026